Chronic Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : April 18, 2026
- Updated On : June 16, 2026
- Pages : 154
Chronic Hepatitis B Market Outlook
Thelansis’s “Chronic Hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hepatitis B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Chronic Hepatitis B Overview
Chronic hepatitis B is a persistent liver infection caused by the hepatitis B virus, a partially double-stranded DNA virus that replicates through an RNA intermediate via reverse transcription. The presence of nuclear covalently closed circular DNA creates viral persistence and acts as the main barrier to a true cure. Transmission occurs via perinatal, sexual, or percutaneous routes, with perinatal exposure carrying the highest risk of chronicity. Contemporary guidelines classify the disease into distinct stages, shifting away from terms like immune tolerant toward HBeAg-positive or HBeAg-negative chronic infection and chronic hepatitis. Diagnoses rely on tracking HBsAg, HBeAg, and HBV DNA levels alongside elastography to map liver fibrosis. Tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir are the preferred first-line nucleos(t)ide analogues to suppress viral replication durably with a high barrier to resistance. While pegylated interferon-alfa offers a finite treatment option, the primary therapeutic goal remains achieving a functional cure, defined by sustained HBsAg loss. The investigational pipeline has moved past failed capsid assembly modulators and is now spearheaded by antisense oligonucleotides like bepirovirsen and targeted small interfering RNAs to suppress viral antigen production. Long-term management requires strict regular surveillance using ultrasound and alpha-fetoprotein to screen for hepatocellular carcinoma.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Chronic Hepatitis B Market Outlook
Thelansis’s “Chronic Hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Hepatitis B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Chronic Hepatitis B Overview
Chronic hepatitis B is a persistent liver infection caused by the hepatitis B virus, a partially double-stranded DNA virus that replicates through an RNA intermediate via reverse transcription. The presence of nuclear covalently closed circular DNA creates viral persistence and acts as the main barrier to a true cure. Transmission occurs via perinatal, sexual, or percutaneous routes, with perinatal exposure carrying the highest risk of chronicity. Contemporary guidelines classify the disease into distinct stages, shifting away from terms like immune tolerant toward HBeAg-positive or HBeAg-negative chronic infection and chronic hepatitis. Diagnoses rely on tracking HBsAg, HBeAg, and HBV DNA levels alongside elastography to map liver fibrosis. Tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir are the preferred first-line nucleos(t)ide analogues to suppress viral replication durably with a high barrier to resistance. While pegylated interferon-alfa offers a finite treatment option, the primary therapeutic goal remains achieving a functional cure, defined by sustained HBsAg loss. The investigational pipeline has moved past failed capsid assembly modulators and is now spearheaded by antisense oligonucleotides like bepirovirsen and targeted small interfering RNAs to suppress viral antigen production. Long-term management requires strict regular surveillance using ultrasound and alpha-fetoprotein to screen for hepatocellular carcinoma.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)